119 related articles for article (PubMed ID: 12167460)
1. Effect of cyclophosphamide on gene expression of cytochromes p450 and beta-actin in the HL-60 cell line.
Xie HJ; Lundgren S; Broberg U; Finnström N; Rane A; Hassan M
Eur J Pharmacol; 2002 Aug; 449(3):197-205. PubMed ID: 12167460
[TBL] [Abstract][Full Text] [Related]
2. Transcript profiling of cytochrome P450 genes in HL-60 human leukemic cells: upregulation of CYP1B1 by all-trans-retinoic acid.
Kawai M; Chen J; Cheung CY; Chang TK
Mol Cell Biochem; 2003 Jun; 248(1-2):57-65. PubMed ID: 12870655
[TBL] [Abstract][Full Text] [Related]
3. Induction of cytochrome P450 (CYP)1A1, CYP1A2, and CYP3A4 but not of CYP2C9, CYP2C19, multidrug resistance (MDR-1) and multidrug resistance associated protein (MRP-1) by prototypical inducers in human hepatocytes.
Runge D; Köhler C; Kostrubsky VE; Jäger D; Lehmann T; Runge DM; May U; Stolz DB; Strom SC; Fleig WE; Michalopoulos GK
Biochem Biophys Res Commun; 2000 Jun; 273(1):333-41. PubMed ID: 10873607
[TBL] [Abstract][Full Text] [Related]
4. Cytochrome P-450 2C9 sensitizes human prostate tumor cells to cyclophosphamide via a bystander effect.
Zhou D; Lu Y; Steiner MS; Dalton JT
Antimicrob Agents Chemother; 2000 Oct; 44(10):2659-63. PubMed ID: 10991840
[TBL] [Abstract][Full Text] [Related]
5. Enantioselective metabolism and cytotoxicity of R-ifosfamide and S-ifosfamide by tumor cell-expressed cytochromes P450.
Chen CS; Jounaidi Y; Waxman DJ
Drug Metab Dispos; 2005 Sep; 33(9):1261-7. PubMed ID: 15919850
[TBL] [Abstract][Full Text] [Related]
6. The effect of repeated administration of cyclophosphamide on cytochrome P450 2B in rats.
Afsharian P; Terelius Y; Hassan Z; Nilsson C; Lundgren S; Hassan M
Clin Cancer Res; 2007 Jul; 13(14):4218-24. PubMed ID: 17634551
[TBL] [Abstract][Full Text] [Related]
7. The effect of cyclophosphamide with and without dexamethasone on cytochrome P450 3A4 and 2B6 in human hepatocytes.
Lindley C; Hamilton G; McCune JS; Faucette S; Shord SS; Hawke RL; Wang H; Gilbert D; Jolley S; Yan B; LeCluyse EL
Drug Metab Dispos; 2002 Jul; 30(7):814-22. PubMed ID: 12065440
[TBL] [Abstract][Full Text] [Related]
8. Effect of inter-individual variability in human liver cytochrome P450 isozymes on cyclophosphamide-induced micronucleus formation.
Kishino Y; Hasegawa T; Kato A; Nishiya Y; Rozhnal V; Watanabe K; Takasaki W; Yamoto T; Mori K
Mutat Res Genet Toxicol Environ Mutagen; 2019 Feb; 838():37-45. PubMed ID: 30678826
[TBL] [Abstract][Full Text] [Related]
9. Retroviral transfer of human cytochrome P450 genes for oxazaphosphorine-based cancer gene therapy.
Jounaidi Y; Hecht JE; Waxman DJ
Cancer Res; 1998 Oct; 58(19):4391-401. PubMed ID: 9766669
[TBL] [Abstract][Full Text] [Related]
10. Mechanisms of retinoid resistance in leukemic cells: possible role of cytochrome P450 and P-glycoprotein.
Kizaki M; Ueno H; Yamazoe Y; Shimada M; Takayama N; Muto A; Matsushita H; Nakajima H; Morikawa M; Koeffler HP; Ikeda Y
Blood; 1996 Jan; 87(2):725-33. PubMed ID: 8555497
[TBL] [Abstract][Full Text] [Related]
11. Activation of the anticancer drugs cyclophosphamide and ifosfamide by cytochrome P450 BM3 mutants.
Vredenburg G; den Braver-Sewradj S; van Vugt-Lussenburg BM; Vermeulen NP; Commandeur JN; Vos JC
Toxicol Lett; 2015 Jan; 232(1):182-92. PubMed ID: 25448283
[TBL] [Abstract][Full Text] [Related]
12. Induction of CYP1A1, CYP1A2, and CYP1B1 mRNAs by nitropolycyclic aromatic hydrocarbons in various human tissue-derived cells: chemical-, cytochrome P450 isoform-, and cell-specific differences.
Iwanari M; Nakajima M; Kizu R; Hayakawa K; Yokoi T
Arch Toxicol; 2002 Jun; 76(5-6):287-98. PubMed ID: 12107646
[TBL] [Abstract][Full Text] [Related]
13. Expression of cytochrome P450 (CYP) enzymes in human nonpigmented ciliary epithelial cells: induction of CYP1B1 expression by TCDD.
Volotinen M; Mäenpää J; Kankuri E; Oksala O; Pelkonen O; Nakajima M; Yokoi T; Hakkola J
Invest Ophthalmol Vis Sci; 2009 Jul; 50(7):3099-105. PubMed ID: 19324859
[TBL] [Abstract][Full Text] [Related]
14. Sensitization of human breast cancer cells to cyclophosphamide and ifosfamide by transfer of a liver cytochrome P450 gene.
Chen L; Waxman DJ; Chen D; Kufe DW
Cancer Res; 1996 Mar; 56(6):1331-40. PubMed ID: 8640822
[TBL] [Abstract][Full Text] [Related]
15. Role of human liver microsomal CYP3A4 and CYP2B6 in catalyzing N-dechloroethylation of cyclophosphamide and ifosfamide.
Huang Z; Roy P; Waxman DJ
Biochem Pharmacol; 2000 Apr; 59(8):961-72. PubMed ID: 10692561
[TBL] [Abstract][Full Text] [Related]
16. Expression of genes encoding for drug metabolising cytochrome P450 enzymes and P-glycoprotein in the rat small intestine; comparison to the liver.
Lindell M; Lang M; Lennernäs H
Eur J Drug Metab Pharmacokinet; 2003; 28(1):41-8. PubMed ID: 14503663
[TBL] [Abstract][Full Text] [Related]
17. Adenoviral delivery of pan-caspase inhibitor p35 enhances bystander killing by P450 gene-directed enzyme prodrug therapy using cyclophosphamide+.
Doloff JC; Su T; Waxman DJ
BMC Cancer; 2010 Sep; 10():487. PubMed ID: 20836875
[TBL] [Abstract][Full Text] [Related]
18. Development of a substrate-activity based approach to identify the major human liver P-450 catalysts of cyclophosphamide and ifosfamide activation based on cDNA-expressed activities and liver microsomal P-450 profiles.
Roy P; Yu LJ; Crespi CL; Waxman DJ
Drug Metab Dispos; 1999 Jun; 27(6):655-66. PubMed ID: 10348794
[TBL] [Abstract][Full Text] [Related]
19. Valproic acid induces CYP3A4 and MDR1 gene expression by activation of constitutive androstane receptor and pregnane X receptor pathways.
Cerveny L; Svecova L; Anzenbacherova E; Vrzal R; Staud F; Dvorak Z; Ulrichova J; Anzenbacher P; Pavek P
Drug Metab Dispos; 2007 Jul; 35(7):1032-41. PubMed ID: 17392393
[TBL] [Abstract][Full Text] [Related]
20. Efficient assessment of the utility of immortalized Fa2N-4 cells for cytochrome P450 (CYP) induction studies using multiplex quantitative reverse transcriptase-polymerase chain reaction (qRT-PCR) and substrate cassette methodologies.
Kenny JR; Chen L; McGinnity DF; Grime K; Shakesheff KM; Thomson B; Riley R
Xenobiotica; 2008 Dec; 38(12):1500-17. PubMed ID: 18989830
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
